Cite
MLA Citation
Robert Chen et al.. “Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087.” Journal for immunotherapy of cancer, vol. 3, no. 2, 2015, pp. 1–2. http://access.bl.uk/ark:/81055/vdc_100080441580.0x000123